Bio-Techne Corporation (TECH)
| Market Cap | 8.37B |
| Revenue (ttm) | 1.22B |
| Net Income (ttm) | 81.06M |
| Shares Out | 156.45M |
| EPS (ttm) | 0.52 |
| PE Ratio | 106.13 |
| Forward PE | 26.80 |
| Dividend | $0.32 (0.60%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 1,618,775 |
| Open | 55.00 |
| Previous Close | 55.11 |
| Day's Range | 52.99 - 55.29 |
| 52-Week Range | 46.05 - 72.16 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 71.82 (+34.22%) |
| Earnings Date | May 6, 2026 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur... [Read more]
Financial Performance
In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for TECH stock is "Strong Buy." The 12-month stock price target is $71.82, which is an increase of 34.22% from the latest price.
News
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The new bran...
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to...
Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced l...
Bio-Techne Transcript: Leerink Global Healthcare Conference 2026
Pharma and China are driving growth, while biotech and academic markets are rebounding as funding returns. Fiscal 2026 guidance is cautious but optimistic, with margin expansion expected through differentiated products and operational improvements.
Bio-Techne Transcript: TD Cowen 46th Annual Health Care Conference
Celebrating its 50th anniversary, the company is leveraging a diversified portfolio and four growth verticals to drive future growth. Strong performance in large pharma and improving biotech funding support confidence in mid-single digit growth by fiscal 2026, while margin expansion and strategic M&A remain key priorities.
Bio-Techne to Present at Upcoming Investor Conferences
MINNEAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference...
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with m...
Bio-Techne Announces Changes to its Leadership Team
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Div...
Bio-Techne Earnings Call Transcript: Q2 2026
Q2 revenue was flat year-over-year, with strong pharma demand offset by biotech and academic softness. Adjusted operating margin expanded to 31.1%, and strategic growth verticals now represent nearly half of revenue. Outlook calls for mid-single-digit underlying growth as headwinds abate.
Biotech firm Bio-Techne beats quarterly estimates on strength in key unit
Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development.
Bio-Techne Declares Dividend
MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31...
Bio-Techne Releases Second Quarter Fiscal 2026 Results
MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights S...
Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Fully defined, synthetic ECM designed to improve reproducibility and reduce lot-to-lot variability Supports standardization of scalable 3D stem cell and organoid workflows Synthetic alternative to tra...
Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
Detects low-abundance proteins in blood at femtogram concentrations for earlier disease insights Supports research in Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury with validat...
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CS...
Bio-Techne Transcript: 44th Annual J.P. Morgan Healthcare Conference
A diversified life sciences company reported $1.2B in 2025 revenue, driven by consumables and strong positions in protein sciences and spatial biology. Despite short-term headwinds from cell therapy customer transitions, innovation and M&A remain central to growth, with improving biotech and academic markets supporting a positive outlook.
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference
MINNEAPOLIS , Dec. 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 2026 J.P. Morgan Health...
Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports com...
Bio-Techne Transcript: 53rd Annual Nasdaq Investor Conference
The business is leveraging its core reagents across four high-growth areas, with recent strong performance in large pharma, China, and product innovation. While cell therapy revenue faces a near-term dip due to Fast Track approvals, long-term prospects remain robust, and market normalization is expected by late 2026.
Bio-Techne Transcript: Citi Annual Global Healthcare Conference 2025
Pharma and academic markets have stabilized, supporting a more optimistic outlook for Biotech, though spending recovery will lag funding improvements. Two major cell therapy customers paused orders, impacting GMP revenue, but long-term commercial potential remains significant. ProteinSimple and Spatial Biology franchises are leading growth, with margin expansion expected in the second half.
Bio-Techne Transcript: Evercore ISI 8th Annual HealthCONx Conference
Organic revenue declined 1% due to cell therapy headwinds, but large pharma and China showed strong growth. Biotech and academic markets are stabilizing, with funding visibility improving. Two major cell therapy customers' Fast Track status creates a temporary revenue gap, but long-term prospects remain strong.
Bio-Techne Transcript: Jefferies London Healthcare Conference 2025
Core growth was up 1% after adjusting for order timing, with large pharma and biotech showing strength, especially in the US, Europe, and China. Innovation and targeted grants expanded the customer base, while M&A remains a priority with capacity for further deals. Headwinds from GMP protein customers are expected to ease after Q4.
Bio-Techne Transcript: Stephens Annual Investment Conference
Pharma and China markets are showing strong growth, while academic and biotech segments are stabilizing. Cell therapy faces short-term headwinds from fast-tracked customers but offers significant long-term potential. Growth verticals and new integrations position the business for double-digit growth as markets normalize.
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration a...
Bio-Techne Transcript: Stifel 2025 Healthcare Conference
Organic revenue declined 1% due to GMP customer order timing, but underlying growth and momentum improved across academic, pharma, and China markets. Product innovation in Spatial and ProteinSimple, strategic investments, and margin management position the business for recovery and a return to double-digit growth as markets stabilize.